Factors Associated With Increased Opioid Use During the COVID-19 Pandemic: A Prospective Study of Patients Enrolled in Opioid Agonist Treatment

被引:8
作者
Rosic, Tea [1 ,2 ]
Naji, Leen [2 ,3 ]
Sanger, Nitika [4 ]
Marsh, David C. [5 ,6 ,7 ,8 ]
Worster, Andrew [2 ,9 ]
Thabane, Lehana [2 ]
Samaan, Zainab [1 ,2 ]
机构
[1] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada
[2] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[3] McMaster Univ, Dept Family Med, Hamilton, ON, Canada
[4] McMaster Univ, Med Sci Grad Program, Hamilton, ON, Canada
[5] Northern Ontario Sch Med, Sudbury, ON, Canada
[6] Canadian Addict Treatment Ctr, Markham, ON, Canada
[7] ICES North, Sudbury, ON, Canada
[8] Hlth Sci North Res Inst, Sudbury, ON, Canada
[9] McMaster Univ, Dept Med, Hamilton, ON, Canada
基金
加拿大健康研究院;
关键词
buprenorphine; COVID-19; methadone; opioid use disorder; SARS-COV-2; USE DISORDER;
D O I
10.1097/ADM.0000000000000939
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Objectives The opioid use disorder (OUD) crisis in North America has become "an epidemic within a pandemic" in the context of the COVID-19 virus. We aimed to explore the association between the COVID-19 pandemic and changes in opioid use patterns among patients receiving treatment for OUD. Methods We used prospectively collected data from 456 patients attending 31 opioid agonist clinics across Ontario, Canada. All included participants underwent routine urine drug screens (UDSs) both before and after the onset of the COVID-19 pandemic. A paired sample t-test was used to compare the proportion of opioid-positive UDSs collected pre- and post-pandemic, and linear regression analysis was used to explore factors associated with this change. Results Participants had a mean age of 39.9 years (standard deviation = 10.9), 52%were male, and 81%were receivingmethadone treatment. The percentage of opioid-positive UDSs increased significantly during the pandemic, on average by 10.6% (95% confidence interval [CI] 8.17, 12.95, P < 0.001). Continued opioid use before the pandemic was associated with 9.43% increase, on average, in the percentage of opioid-positive UDSs during the pandemic (95% CI 3.79, 15.07). Self-reported past-month cocaine (adjusted betacoefficient 6.83, 95% CI 0.92, 12.73) and amphetamine (adjusted beta-coefficient 13.13, 95% CI 5.15, 21.1) use at study entry were also associated with increases in opioid-positive UDSs. Conclusions Increased opioid use is one measure of the negative impact the COVID-19 pandemic has had on individuals with OUD, an already marginalized population. Understanding factors associated with worse outcomes is essential to ensuring that treatment programs appropriately adapt to better serve this population during the pandemic.
引用
收藏
页码:E257 / E264
页数:8
相关论文
共 50 条
[21]   Treatment experience for opioid use disorder during COVID-19 in India: Learning from patients [J].
Pandit, Prabhat Mani ;
Bhatia, Gayatri ;
Sarkar, Siddharth .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2020, 119
[22]   The Odyssey of HOMER: Comparative Effectiveness Research on Medication for Opioid Use Disorder During the COVID-19 Pandemic [J].
Zittleman, Linda ;
Westfall, John M. ;
Sofie, Benjamin ;
Lutgen, Cory ;
Fernald, Douglas ;
Hall, Tristen L. ;
Hochheimer, Camille J. ;
Murphy, Melanie ;
Felzien, Maret ;
Dickinson, L. Miriam ;
Manning, Brian K. ;
LeMaster, Joseph ;
Nease Jr, Donald E. .
ANNALS OF FAMILY MEDICINE, 2024, 22 (05) :444-450
[23]   Perceived risk, attitudes, and behavior of cigarette smokers and nicotine vapers receiving buprenorphine treatment for opioid use disorder during the COVID-19 pandemic [J].
Streck, Joanna M. ;
Kalkhoran, Sara ;
Bearnot, Benjamin ;
Gupta, Priya S. ;
Kalagher, Kelly M. ;
Regan, Susan ;
Wakeman, Sarah ;
Rigotti, Nancy A. .
DRUG AND ALCOHOL DEPENDENCE, 2021, 218
[24]   Effect of Didactic Training on Barriers and Biases to Treatment of Opioid Use Disorder: Meeting the Ongoing Needs of Patients with Opioid Use Disorder in the Emergency Department during the COVID-19 Pandemic [J].
Johnson, Emily ;
Bolshakova, Maria ;
Vosooghi, Aidan ;
Lam, Chun Nok ;
Trotzky-Sirr, Rebecca ;
Bluthenthal, Ricky ;
Schneberk, Todd .
HEALTHCARE, 2022, 10 (12)
[25]   Opioid treatment program safety measures during the COVID-19 pandemic: a statewide survey [J].
Bandara, Sachini ;
Maniates, Hannah ;
Hulsey, Eric ;
Smith, Jennifer S. ;
DiDomenico, Ellen ;
Stuart, Elizabeth A. ;
Saloner, Brendan ;
Krawczyk, Noa .
BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
[26]   Opioid treatment program safety measures during the COVID-19 pandemic: a statewide survey [J].
Sachini Bandara ;
Hannah Maniates ;
Eric Hulsey ;
Jennifer S. Smith ;
Ellen DiDomenico ;
Elizabeth A. Stuart ;
Brendan Saloner ;
Noa Krawczyk .
BMC Health Services Research, 22
[27]   COVID-19 and treating incarcerated populations for opioid use disorder [J].
Donelan, Christopher J. ;
Hayes, Edmond ;
Potee, Ruth A. ;
Schwartz, Levin ;
Evans, Elizabeth A. .
JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2021, 124
[28]   Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review [J].
Noa Krawczyk ;
Adetayo Fawole ;
Jenny Yang ;
Babak Tofighi .
Addiction Science & Clinical Practice, 16
[29]   Clinician Perspectives on Delivering Medication Treatment for Opioid Use Disorder during the COVID-19 Pandemic: A Qualitative Evaluation [J].
Lott, Aline M. ;
Danner, Anissa N. ;
Malte, Carol A. ;
Williams, Emily C. ;
Gordon, Adam J. ;
Halvorson, Max A. ;
Saxon, Andrew J. ;
Hagedorn, Hildi J. ;
Sayre, George G. ;
Hawkins, Eric J. .
JOURNAL OF ADDICTION MEDICINE, 2023, 17 (04) :E262-E268
[30]   A national model of remote care for assessing and providing opioid agonist treatment during the COVID-19 pandemic: a report [J].
Crowley, Des ;
Delargy, Ide .
HARM REDUCTION JOURNAL, 2020, 17 (01)